JO3261B1 - مشتق بيريدين أحادي الحلقة - Google Patents

مشتق بيريدين أحادي الحلقة

Info

Publication number
JO3261B1
JO3261B1 JOP/2014/0039A JOP20140039A JO3261B1 JO 3261 B1 JO3261 B1 JO 3261B1 JO P20140039 A JOP20140039 A JO P20140039A JO 3261 B1 JO3261 B1 JO 3261B1
Authority
JO
Jordan
Prior art keywords
group
hydrogen atom
present
alkoxy
pharmaceutically acceptable
Prior art date
Application number
JOP/2014/0039A
Other languages
English (en)
Inventor
Ohashi Isao
Okada Toshimi
Nagao Satoshi
Funasaka Setsuo
Tanaka Keigo
Nakatani Yusuke
Yamane Yoshinobu
Karoji Yuki
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of JO3261B1 publication Critical patent/JO3261B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتقديم مركب جديد له نشاط مثبط لـ FGFR أو ملح مقبول صيدلانيا منه، وتركيبة صيدلانية تتضمنه. بصفة خاصة، يقدم الاختراع الحالي مركب ممثل بالصيغة التالية (I) أو ملح مقبول صيدلانيا منه: حيث n تمثل 0 الى 2؛ A تمثل مجموعة أريلين أو مجموعة أريلين غير متجانسة؛ G تمثل رابطة فردية، ذرة أكسجين أو -CH 2 - ؛ E تمثل سيكل غير متجانسة غير عطرية تتضمن نيتروجين؛ R1 تمثل مجموعة ألكوكسي، مجموعة ألكوكسي ألكوكسي أو ما شابه ذلك؛ R2 تمثل ذرة هيدروجين، ذرة هالوجين، مجموعة هيدروكسيل، مجموعة ألكيل، مجموعة هيدروكسي ألكيل، مجموعة سيكليك غير متجانسة غير عطرية تتضمن نيتروجين أو ما شابه ذلك؛ و R3 تمثل ذرة هيدروجين، مجموعة ألكيل، مجموعة ألكوكسي أو ما شابه ذلك، بشرط أنه عندما تكون E تمثل حلقة أزيتيدين و R2 أو تكون R3 موجودة على ذرة نيتروجين على حلقة الأزيتيدين، R2 أو R3 لا تمثل ذرة هيدروجين.
JOP/2014/0039A 2013-02-20 2014-02-18 مشتق بيريدين أحادي الحلقة JO3261B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361766922P 2013-02-20 2013-02-20

Publications (1)

Publication Number Publication Date
JO3261B1 true JO3261B1 (ar) 2018-09-16

Family

ID=51351646

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0039A JO3261B1 (ar) 2013-02-20 2014-02-18 مشتق بيريدين أحادي الحلقة

Country Status (35)

Country Link
US (1) US8933099B2 (ar)
EP (1) EP2960238B1 (ar)
JP (2) JP5600229B1 (ar)
KR (1) KR102050128B1 (ar)
CN (1) CN105073730B (ar)
AR (1) AR094812A1 (ar)
AU (1) AU2014219811B2 (ar)
BR (1) BR112015019790B1 (ar)
CA (1) CA2901585C (ar)
CL (1) CL2015002311A1 (ar)
CY (1) CY1119220T1 (ar)
DK (1) DK2960238T3 (ar)
ES (1) ES2628495T3 (ar)
HR (1) HRP20170873T1 (ar)
HU (1) HUE032931T2 (ar)
IL (1) IL240623B (ar)
JO (1) JO3261B1 (ar)
LT (1) LT2960238T (ar)
ME (1) ME02755B (ar)
MX (1) MX361870B (ar)
MY (1) MY178760A (ar)
NZ (1) NZ711101A (ar)
PE (1) PE20151509A1 (ar)
PH (1) PH12015501813A1 (ar)
PL (1) PL2960238T3 (ar)
PT (1) PT2960238T (ar)
RS (1) RS56064B1 (ar)
RU (1) RU2645352C2 (ar)
SG (1) SG11201506488WA (ar)
SI (1) SI2960238T1 (ar)
SM (1) SMT201700288T1 (ar)
TW (4) TWI672140B (ar)
UA (1) UA116794C2 (ar)
WO (1) WO2014129477A1 (ar)
ZA (1) ZA201505941B (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX369646B (es) * 2014-08-18 2019-11-15 Eisai R&D Man Co Ltd Sal de derivado de piridina monociclico y su cristal.
AU2016237222B2 (en) * 2015-03-25 2021-04-29 Eisai R&D Management Co., Ltd. Therapeutic agent for bile duct cancer
CA3001969C (en) * 2015-12-17 2023-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
US20200297711A1 (en) * 2017-10-12 2020-09-24 Eisai R&D Management Co., Ltd. Pharmaceutical composition comprising fgfr selective tyrosine kinase inhibitor
JPWO2019189241A1 (ja) 2018-03-28 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021210636A1 (ja) 2020-04-17 2021-10-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤
CA3185174A1 (en) 2020-07-31 2022-02-03 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
US20230330081A1 (en) 2020-10-28 2023-10-19 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
CN117715902A (zh) * 2021-08-31 2024-03-15 卫材R&D管理有限公司 单环吡啶衍生物的制造方法
JP2023099778A (ja) * 2021-08-31 2023-07-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の製造方法
WO2023032872A1 (ja) 2021-08-31 2023-03-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の合成中間体の製造方法
JP2023099776A (ja) * 2021-08-31 2023-07-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の合成中間体の製造方法
JP7802200B2 (ja) * 2022-03-18 2026-01-19 上▲海▼▲潤▼石医▲薬▼科技有限公司 置換のアミノ６員窒素複素環式化合物の塩及びその結晶形、製造方法と応用
WO2025061013A1 (zh) * 2023-09-18 2025-03-27 上海润石医药科技有限公司 包含杂芳基氧基萘类化合物的药物组合物及其制备方法和应用
TW202606671A (zh) * 2024-06-27 2026-02-16 日商衛材R&D企管股份有限公司 用於預測患有腫瘤的人類受試者的響應可能性之方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
EP1375465A4 (en) 2001-04-03 2006-01-11 Eisai Co Ltd CYCLOOCTANON DERIVATIVE AND CYCLODECANON DERIVATIVE AND THEIR USE
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2004020434A1 (ja) * 2002-08-30 2004-03-11 Eisai Co., Ltd. 含窒素芳香環誘導体
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2006522756A (ja) 2003-04-10 2006-10-05 エフ．ホフマン−ラ　ロシュ　アーゲー ピリミド化合物
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
EP2270000B1 (en) * 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
WO2007071752A2 (en) 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1891955A1 (en) 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
EP2114941B1 (en) 2006-12-22 2015-03-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
WO2009001070A1 (en) 2007-06-25 2008-12-31 Qinetiq Limited Heater suitable for use in a preconcentrator device
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
WO2009076660A2 (en) * 2007-12-13 2009-06-18 Tyratech, Inc. Organic absorbent material and uses thereof
CL2008003675A1 (es) * 2007-12-13 2009-03-20 Wyeth Corp Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide.
JP5351254B2 (ja) 2008-05-23 2013-11-27 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2009153592A1 (en) 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
EP2379556A1 (en) 2008-12-30 2011-10-26 ArQule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
US8263610B2 (en) 2008-12-30 2012-09-11 Arqule, Inc. Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds
ES2554623T3 (es) 2008-12-30 2015-12-22 Arqule, Inc. Compuestos de 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituida
US9002427B2 (en) 2009-03-30 2015-04-07 Lifewave Biomedical, Inc. Apparatus and method for continuous noninvasive measurement of respiratory function and events
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
AR084370A1 (es) 2009-08-07 2013-05-15 Chugai Pharmaceutical Co Ltd Derivados de aminopirazol
ES2524548T3 (es) 2009-10-30 2014-12-10 Novartis Ag N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
MX351513B (es) 2012-01-19 2017-10-17 Taiho Pharmaceutical Co Ltd Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo.
UA114501C2 (uk) 2012-02-28 2017-06-26 Астеллас Фарма Інк. Азотовмісна ароматична гетероциклічна сполука
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
CA2886002C (en) 2012-09-27 2020-06-09 Chugai Seiyaku Kabushiki Kaisha Fgfr3 fusion gene and pharmaceutical drug targeting same
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑

Also Published As

Publication number Publication date
NZ711101A (en) 2018-08-31
WO2014129477A1 (ja) 2014-08-28
TW201902889A (zh) 2019-01-16
TWI672140B (zh) 2019-09-21
US20140235614A1 (en) 2014-08-21
JP5600229B1 (ja) 2014-10-01
ME02755B (me) 2018-01-20
PE20151509A1 (es) 2015-10-18
PT2960238T (pt) 2017-06-05
LT2960238T (lt) 2017-07-10
TWI672296B (zh) 2019-09-21
MX2015010698A (es) 2016-04-11
TW201900169A (zh) 2019-01-01
JP2014237707A (ja) 2014-12-18
BR112015019790A2 (pt) 2017-07-18
RU2015134558A (ru) 2017-03-24
HRP20170873T1 (hr) 2017-09-08
AU2014219811A1 (en) 2015-09-03
TWI672139B (zh) 2019-09-21
BR112015019790B1 (pt) 2020-12-01
DK2960238T3 (en) 2017-06-26
SMT201700288T1 (it) 2017-07-18
AR094812A1 (es) 2015-08-26
TWI641602B (zh) 2018-11-21
SG11201506488WA (en) 2015-09-29
SI2960238T1 (sl) 2017-07-31
CA2901585A1 (en) 2014-08-28
PL2960238T3 (pl) 2017-09-29
MY178760A (en) 2020-10-20
IL240623A0 (en) 2015-10-29
ZA201505941B (en) 2016-07-27
EP2960238A4 (en) 2016-08-17
EP2960238B1 (en) 2017-04-05
HUE032931T2 (en) 2017-11-28
RU2645352C2 (ru) 2018-02-21
KR102050128B1 (ko) 2019-11-28
UA116794C2 (uk) 2018-05-10
PH12015501813A1 (en) 2015-12-07
CN105073730B (zh) 2017-10-13
CN105073730A (zh) 2015-11-18
AU2014219811B2 (en) 2017-09-28
US8933099B2 (en) 2015-01-13
HK1215949A1 (en) 2016-09-30
IL240623B (en) 2019-03-31
KR20150118151A (ko) 2015-10-21
TW201439085A (zh) 2014-10-16
MX361870B (es) 2018-12-18
TW201900168A (zh) 2019-01-01
CL2015002311A1 (es) 2016-02-05
RS56064B1 (sr) 2017-10-31
JPWO2014129477A1 (ja) 2017-02-02
ES2628495T3 (es) 2017-08-03
CY1119220T1 (el) 2018-02-14
EP2960238A1 (en) 2015-12-30
CA2901585C (en) 2019-09-24

Similar Documents

Publication Publication Date Title
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
UA118259C2 (uk) Гетероциклічні аміди як інгібітори кінази
MX2017010735A (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
EA201690127A1 (ru) Состав на основе ингибиторов syk
NZ710052A (en) Novel pyrazol derivatives
MX2017005158A (es) Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk).
IN2014DN07283A (ar)
PH12018501181A1 (en) Phenyl derivatives as cannabinoid receptor 2 agonists
MX368178B (es) Compuestos de ácido dimetilbenzoico.
MX2015017156A (es) Inhibidores de bace.
PH12020500292A1 (en) Pyridine compound substituted with azole
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
PH12018502012B1 (en) Griseofulvin compound
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
PH12016500152A1 (en) Novel triazine derivative
EP3769757A3 (en) Imaging histone deacetylases with a radiotracer using positron emission tomography
MD20150103A2 (ro) Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
MX2015007309A (es) Derivado de hidantoina.
BR112015023280A2 (pt) derivados de dihidroquinolin-2-ona para utilização como inibidores da aldosterona sintase
PH12016501645A1 (en) Aminopyrazolone derivative